Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2026-05-22 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2025年年度股东会会议资料
AGM Information Classification · 88% confidence The document is clearly titled “2025年年度股东会会议资料” (2025 Annual General Meeting Meeting Materials) for Shanghai Yitai Pharmaceutical Technology Co., Ltd. It contains the AGM notice, agenda, detailed proposals for dividends, board elections, governance rule amendments, audit appointments, etc.—all typical of annual shareholders’ meeting materials. It is not a financial report or earnings release but rather the materials provided to shareholders for the AGM. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-22 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings Classification · 82% confidence The document is a ‘现场检查报告’ prepared by the sponsor (Guotai Huatong) under Shanghai Stock Exchange and CSRC rules concerning continuous supervision of an issuer. It is a regulatory compliance report filed to the exchange, not an annual or interim financial report, not an audit opinion, not a board change announcement, nor any other specific category. It belongs in the general Regulatory Filings (RNS) fallback category.
2026-05-20 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司2025年度持续督导年度跟踪报告
Regulatory Filings Classification · 75% confidence The document is titled “2025年度持续督导年度跟踪报告” issued by the sponsor (Guotai Haitong Securities) regarding its ongoing supervision of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. This is not an annual or interim report by the company itself, nor an earnings release, audit, proxy, or transaction notice. It is a continuous‐supervision compliance report required by the exchange. It does not fit any specific category except as a general regulatory/compliance filing. Therefore, it falls into the fallback category “Regulatory Filings (RNS).”
2026-05-20 Chinese
2025年度环境、社会和公司治理报告摘要
Regulatory Filings
2026-04-29 Chinese
董事会审计委员会对会计师事务所2025年度履行监督职责情况的报告
Regulatory Filings
2026-04-29 Chinese
第二届董事会第二十六次会议决议公告
Regulatory Filings
2026-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.